Waters Corporation $WAT Stake Lifted by ABN Amro Investment Solutions

ABN Amro Investment Solutions grew its position in shares of Waters Corporation (NYSE:WAT) by 125.2% during the 1st quarter, Holdings Channel reports. The firm owned 4,000 shares of the medical instruments supplier’s stock after purchasing an additional 2,224 shares during the period. ABN Amro Investment Solutions’ holdings in Waters were worth $1,191,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Zions Bancorporation National Association UT boosted its stake in Waters by 121.2% during the fourth quarter. Zions Bancorporation National Association UT now owns 73 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 40 shares in the last quarter. SHP Wealth Management acquired a new stake in Waters in the 4th quarter valued at about $32,000. DV Equities LLC acquired a new stake in Waters in the 4th quarter valued at about $32,000. Anchor Investment Management LLC bought a new position in shares of Waters during the 1st quarter valued at about $27,000. Finally, Vision Retirement LLC acquired a new position in shares of Waters in the 1st quarter worth approximately $29,000. Institutional investors and hedge funds own 94.01% of the company’s stock.

Waters Stock Performance

Shares of WAT stock opened at $374.49 on Friday. The company has a market capitalization of $36.77 billion, a price-to-earnings ratio of 47.59, a P/E/G ratio of 2.27 and a beta of 1.20. Waters Corporation has a 1-year low of $275.05 and a 1-year high of $414.15. The company has a current ratio of 1.79, a quick ratio of 1.13 and a debt-to-equity ratio of 0.32. The stock’s fifty day simple moving average is $365.23 and its 200-day simple moving average is $346.13.

Waters (NYSE:WAT) last released its earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.31 by $0.39. The company had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.20 billion. Waters had a return on equity of 15.60% and a net margin of 11.91%.The business’s revenue for the quarter was up 91.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.25 EPS. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. On average, sell-side analysts predict that Waters Corporation will post 14.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Bank of America raised their price objective on Waters from $370.00 to $400.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 2nd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $350.00 target price on shares of Waters in a report on Thursday, May 7th. Guggenheim reiterated a “buy” rating and issued a $440.00 price target on shares of Waters in a research report on Wednesday, July 8th. Wall Street Zen cut Waters from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Finally, Evercore reaffirmed an “outperform” rating and set a $410.00 price objective on shares of Waters in a research note on Monday, July 6th. Three investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $401.60.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.